dc.contributor.author |
Farhat M.H. |
dc.contributor.author |
El-Saghir N.S. |
dc.contributor.author |
Shamseddine A.I. |
dc.contributor.editor |
|
dc.date |
2008 |
dc.date.accessioned |
2017-10-05T15:37:32Z |
dc.date.available |
2017-10-05T15:37:32Z |
dc.date.issued |
2008 |
dc.identifier |
|
dc.identifier.isbn |
|
dc.identifier.issn |
02564947 |
dc.identifier.uri |
http://hdl.handle.net/10938/15774 |
dc.description.abstract |
[No abstract available] |
dc.format.extent |
|
dc.format.extent |
Pages: (374-377) |
dc.language |
English |
dc.publisher |
RIYADH |
dc.relation.ispartof |
Publication Name: Annals of Saudi Medicine; Publication Year: 2008; Volume: 28; no. 5; Pages: (374-377); |
dc.relation.ispartofseries |
|
dc.relation.uri |
|
dc.source |
Scopus |
dc.subject.other |
|
dc.title |
Hand-foot syndrome with docetaxel: A five-case series |
dc.type |
Article |
dc.contributor.affiliation |
Farhat, M.H., Department of Internal Medicine, American University of Beirut Medical Center, PO Box 11-0236-E21, Raid El Solh, Beirut 11070720, Lebanon |
dc.contributor.affiliation |
El-Saghir, N.S., Department of Internal Medicine, American University of Beirut Medical Center, PO Box 11-0236-E21, Raid El Solh, Beirut 11070720, Lebanon |
dc.contributor.affiliation |
Shamseddine, A.I., Department of Hematology-Oncology, American University of Beirut, PO Box 11-0236-E21, Raid El Solh, Beirut 11070720, Lebanon |
dc.contributor.authorAddress |
Farhat, M.H.; Department of Internal Medicine, American University of Beirut Medical Center, PO Box 11-0236-E21, Raid El Solh, Beirut 11070720, Lebanon; email: bellanotchi@hotmail.com |
dc.contributor.authorCorporate |
University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine; |
dc.contributor.authorDepartment |
Internal Medicine |
dc.contributor.authorDivision |
|
dc.contributor.authorEmail |
bellanotchi@hotmail.com |
dc.contributor.faculty |
Faculty of Medicine |
dc.contributor.authorInitials |
Farhat, MH |
dc.contributor.authorInitials |
El-Saghir, NS |
dc.contributor.authorInitials |
Shamseddine, AI |
dc.contributor.authorOrcidID |
|
dc.contributor.authorReprintAddress |
Farhat, MH (reprint author), Amer Univ Beirut, Med Ctr, Dept Internal Med, POB 11-0236-E21, Beirut 11070720, Lebanon. |
dc.contributor.authorResearcherID |
|
dc.contributor.authorUniversity |
American University of Beirut Medical Center |
dc.description.cited |
Abushullaih S, 2002, CANCER INVEST, V20, P3, DOI 10.1081-CNV-120000360; Asgari MM, 1999, J CUTAN PATHOL, V26, P287, DOI 10.1111-j.1600-0560.1999.tb01846.x; BARDIA A, 2006, J CLIN ONCOL, V24, P184; Chu CY, 2000, BRIT J DERMATOL, V142, P808, DOI 10.1046-j.1365-2133.2000.03432.x; Crawford JH, 2002, EUR J HAEMATOL, V69, P315, DOI 10.1034-j.1600-0609.2002.02834.x; D'Agostino G, 2003, BRIT J CANCER, V89, P1180, DOI 10.1038-sj.bjc.6601284; Eich D, 2002, AM J CLIN ONCOL-CANC, V25, P599, DOI 10.1097-00000421-200212000-00015; Feizy Vida, 2003, Dermatol Online J, V9, P14; GORDON KB, 1995, CANCER, V75, P2169, DOI 10.1002-1097-0142(19950415)75:82169::AID-CNCR28207508223.0.CO;2-H; Gressett Sarah M, 2006, J Oncol Pharm Pract, V12, P131, DOI 10.1177-1078155206069242; Hui YF, 2000, PHARMACOTHERAPY, V20, P1221, DOI 10.1592-phco.20.15.1221.34593; Kara IG, 2006, BREAST, V15, P414, DOI 10.1016-j.breast.2005.07.007; Katoh M, 2004, J DERMATOL, V31, P403; Laack E, 2001, ANN ONCOL, V12, P1761, DOI 10.1023-A:1013575816870; Lin E, 2002, ONCOLOGY-NY, V16, P31; LIN EH, 2002, P AM SOC CLIN ONCOL, V21; Lopez AM, 1999, CANCER CHEMOTH PHARM, V44, P303, DOI 10.1007-s002800050981; Mrozek E, 2006, CLIN BREAST CANCER, V7, P141, DOI 10.3816-CBC.2006.n.023; Nagore E, 2000, Am J Clin Dermatol, V1, P225, DOI 10.2165-00128071-200001040-00004; O'Brien MER, 2004, ANN ONCOL, V15, P440, DOI 10.1093-annone-mdh097; PORTAL I, 1994, CANCER CHEMOTH PHARM, V34, P181, DOI 10.1007-BF00685939; Razis E, 2006, CANCER INVEST, V24, P514, DOI 10.1080-07357900600814847; Saif MW, 2006, CLIN COLORECTAL CANC, V6, P219, DOI 10.3816-CCC.2006.n.039; SCHEITHAUER W, 2004, ONCOLOGY WILLISTON P, V18, P1173; SCHEITHAUER W, 2004, ONCOLOGY WILLISTON P, V18, P1181; Scheithauer W, 2004, ONCOLOGY-NY, V18, P1161; Schrijvers D, 2000, BRIT J DERMATOL, V142, P1069, DOI 10.1046-j.1365-2133.2000.03518.x; Scotte F, 2005, J CLIN ONCOL, V23, P4424, DOI 10.1200-JCO.2005.15.651; SILVER FS, 1983, ANN INTERN MED, V98, P675; Vail DM, 1998, CLIN CANCER RES, V4, P1567; VUKELJA SJ, 1993, J NATL CANCER I, V85, P1432, DOI 10.1093-jnci-85.17.1432; Wilkes Gail M, 2005, Clin J Oncol Nurs, V9, P103; ZIMMERMAN GC, 1995, ARCH DERMATOL, V131, P202, DOI 10.1001-archderm.131.2.202; ZIMMERMAN GC, 1994, J NATL CANCER I, V86, P557, DOI 10.1093-jnci-86.7.557; ZUEHLKE RL, 1974, DERMATOLOGICA, V148, P90 |
dc.description.citedCount |
4 |
dc.description.citedTotWOSCount |
2 |
dc.description.citedWOSCount |
2 |
dc.format.extentCount |
4 |
dc.identifier.articleNo |
|
dc.identifier.coden |
ANSME |
dc.identifier.pubmedID |
|
dc.identifier.scopusID |
58249091942 |
dc.identifier.url |
|
dc.publisher.address |
PUBLICATIONS OFFICE PO BOX 3354, RIYADH 11211, SAUDI ARABIA |
dc.relation.ispartofConference |
|
dc.relation.ispartofConferenceCode |
|
dc.relation.ispartofConferenceDate |
|
dc.relation.ispartofConferenceHosting |
|
dc.relation.ispartofConferenceLoc |
|
dc.relation.ispartofConferenceSponsor |
|
dc.relation.ispartofConferenceTitle |
|
dc.relation.ispartofFundingAgency |
|
dc.relation.ispartOfISOAbbr |
Ann. Saudi Med. |
dc.relation.ispartOfIssue |
5 |
dc.relation.ispartOfPart |
|
dc.relation.ispartofPubTitle |
Annals of Saudi Medicine |
dc.relation.ispartofPubTitleAbbr |
Ann. Saudi Med. |
dc.relation.ispartOfSpecialIssue |
|
dc.relation.ispartOfSuppl |
|
dc.relation.ispartOfVolume |
28 |
dc.source.ID |
WOS:000261007000009 |
dc.type.publication |
Journal |
dc.subject.otherAuthKeyword |
|
dc.subject.otherChemCAS |
cyclophosphamide, 50-18-0 |
dc.subject.otherChemCAS |
docetaxel, 114977-28-5 |
dc.subject.otherChemCAS |
doxorubicin, 23214-92-8, 25316-40-9 |
dc.subject.otherChemCAS |
epirubicin, 56390-09-1, 56420-45-2 |
dc.subject.otherChemCAS |
fluorouracil, 51-21-8 |
dc.subject.otherChemCAS |
letrozole, 112809-51-5 |
dc.subject.otherChemCAS |
paclitaxel, 33069-62-4 |
dc.subject.otherChemCAS |
recombinant granulocyte colony stimulating factor, 121181-53-1 |
dc.subject.otherIndex |
cyclophosphamide |
dc.subject.otherIndex |
docetaxel |
dc.subject.otherIndex |
doxorubicin |
dc.subject.otherIndex |
emollient agent |
dc.subject.otherIndex |
epirubicin |
dc.subject.otherIndex |
fluorouracil |
dc.subject.otherIndex |
letrozole |
dc.subject.otherIndex |
paclitaxel |
dc.subject.otherIndex |
recombinant granulocyte colony stimulating factor |
dc.subject.otherIndex |
steroid |
dc.subject.otherIndex |
adjuvant therapy |
dc.subject.otherIndex |
adult |
dc.subject.otherIndex |
aged |
dc.subject.otherIndex |
article |
dc.subject.otherIndex |
breast cancer |
dc.subject.otherIndex |
cancer adjuvant therapy |
dc.subject.otherIndex |
clinical article |
dc.subject.otherIndex |
drug substitution |
dc.subject.otherIndex |
drug withdrawal |
dc.subject.otherIndex |
female |
dc.subject.otherIndex |
hand foot syndrome |
dc.subject.otherIndex |
human |
dc.subject.otherIndex |
mastectomy |
dc.subject.otherIndex |
monotherapy |
dc.subject.otherIndex |
multiple cycle treatment |
dc.subject.otherIndex |
priority journal |
dc.subject.otherIndex |
skin biopsy |
dc.subject.otherIndex |
treatment refusal |
dc.subject.otherKeywordPlus |
PALMAR-PLANTAR ERYTHRODYSESTHESIA |
dc.subject.otherKeywordPlus |
METASTATIC BREAST-CANCER |
dc.subject.otherKeywordPlus |
LIPOSOMAL DOXORUBICIN |
dc.subject.otherKeywordPlus |
CUTANEOUS TOXICITY |
dc.subject.otherKeywordPlus |
ACRAL ERYTHEMA |
dc.subject.otherKeywordPlus |
PHASE-II |
dc.subject.otherKeywordPlus |
CAPECITABINE |
dc.subject.otherKeywordPlus |
THERAPY |
dc.subject.otherKeywordPlus |
GEMCITABINE |
dc.subject.otherKeywordPlus |
PYRIDOXINE |
dc.subject.otherWOS |
Medicine, General and Internal |